They are approved for the treatment of breast, ovarian, prostate, and pancreatic cancer, which are the solid tumor types most frequently associated with loss of function mutations in key HR genes such as BRCA1/22. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.